cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Blueprint Medicines Corp
4 own
5 watching
Current Price
$45.65
$-3.41
(-6.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,730.26M
52-Week High
52-Week High
85.67
52-Week Low
52-Week Low
40.78
Average Volume
Average Volume
0.81M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
17.8934
iconMarket Capitalization2,730.26M
icon52-Week High85.67
icon52-Week Low40.78
iconAverage Volume0.81M
iconDividend Yield--
iconP/E Ratio17.8934
What does the Blueprint Medicines Corp do?
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Blueprint Medicines Corp make?
News & Events about Blueprint Medicines Corp.
PR Newswire
2days ago
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual...
Ticker Report
22days ago
Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) has received a consensus recommendation of Moderate Buy from the nineteen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given...
PR Newswire
30days ago
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors PR Newswire CAMBRIDGE, Mass., Jan. 6, 2023 CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the...
Zolmax
2 months ago
Shares of Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) have been assigned a consensus rating of Hold from the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold ...
Ticker Report
2 months ago
Shares of Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) have been assigned a consensus rating of Hold from the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ...
Frequently Asked Questions
Frequently Asked Questions
What is Blueprint Medicines Corp share price today?
plus_minus_icon
Can Indians buy Blueprint Medicines Corp shares?
plus_minus_icon
How can I buy Blueprint Medicines Corp shares from India?
plus_minus_icon
Can Fractional shares of Blueprint Medicines Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Blueprint Medicines Corp stocks?
plus_minus_icon
What is today’s traded volume of Blueprint Medicines Corp?
plus_minus_icon
What is today’s market capitalisation of Blueprint Medicines Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Blueprint Medicines Corp?
plus_minus_icon
What percentage is Blueprint Medicines Corp down from its 52-Week High?
plus_minus_icon
What percentage is Blueprint Medicines Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$45.65
$-3.41
(-6.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00